Precision oncology therapies account for nearly half of new cancer drug approvals sin
Of the 198 new oncology drugs approved by the U.S. Food and Drug Administration (FDA) between 1998 and 2022, approximately 43% were precision oncology therapies, the use of which is guided by biomarker testing.
Linear Mode
